BTG3 and arthritic joint disease: In psoriatic patients treated with infliximab (with or without arthritis), the prevalence of ANA always increased: respectively from 11 to 72% [17], from 9 to 48% [30], and from 22 to 63% [22] with a gradual increase both in ANA titer and in percentage of ANA pattern even restricted for anti dsDNA and anti nucleosome [20,22].